AstraZeneca plc vs GoPro Inc — how do they compare? AstraZeneca plc trades at $158.2 (market cap $248.14B), while GoPro Inc trades at $0.59 (market cap $114.41M). The key difference: AstraZeneca plc is far larger — about 2168.9× GoPro Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| AZN | GPRO | |
|---|---|---|
Market Cap | $248.14B | $114.41M |
Sector | Health | Technology |
52-Week High | $209.48 | $2.88 |
52-Week Low | $147.06 | $0.62 |
Enterprise Value | $275.41B | $173.19M |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
GoPro (GPRO) trades at $0.70, down 3.53% in the last 24 hours, reflecting ongoing financial distress with a net income margin of -28.52% and negative cash flow. The stock is technically bearish, with moving averages signaling sell pressure, while recent news highlights a strategic review for a potential sale. Revenue has declined from $1.1B in 2022 to $652M in 2025, with consistent earnings misses and negative equity of -$681.61M.
The outlook hinges on the outcome of the strategic sale process, offering speculative upside if a buyer emerges, but risks include persistent cash burn, competitive pressures, and weak sales trends. Analysts are cautious, with only 21.43% recommending buy, as the company faces going-concern risks and dilution from financing activities.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →